ARXX Therapeutics ApS: Financial statements 2023
CVR: 40868151
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ARXX Therapeutics ApS (CVR 40868151) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 2,790,576 and a net result of DKK 269,759 compared with DKK 507,105 the year before. That is a decrease of 51.8% compared with the year before. The profit margin was 9.7%. Equity in the 2023 report amounted to DKK 865,480. The solvency ratio was 70.9%.
- Revenue
- DKK 2,790,576
- Gross Profit
- DKK 1,877,759
- Profit/Loss
- DKK 269,759
- Equity
- DKK 865,480
- Total Assets
- DKK 1,220,625
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 2.8M | 1.9M | 270K | 865K | - |
| 2022 | 5.8M | 2.2M | 507K | 596K | - |
| 2021 | 2.4M | 1.7M | 77K | 177K | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ARXX Therapeutics ApS has published its annual report for 2022. Revenue came to DKK 5,789,922, and the net result was DKK 507,105.
About ARXX Therapeutics ApS
ARXX Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Berte Aagot Hedding Poulsson and Jonas Hallén. The company is owned by ARXX THERAPEUTICS AS. The company has 2 employees (2026). In 2025, the company reported revenue of DKK 3,743,522 and a net result of DKK 706,595 compared with DKK 116,729 the year before. Equity in the 2025 report amounted to DKK 1,688,804.